PrimeRFP SCOUT · Federal Contract Recompete Brief

SPE2DR26FQQJ94571034480!gamifant 100 MG 20 ML VIAL 20ml — Dms Pharmaceutical Group Inc

Dms Pharmaceutical Group Inc holds $737.3M across 100,503 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award under parent SPE2DR25D9331. PoP ended Mar 20, 2026 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Dla Troop Support

Awarding office

Dms Pharmaceutical Group Inc

Recipient

Mar 20, 2026

PoP end

$275K

Obligated

$275K

Potential

424210

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Dms Pharmaceutical Group Inc — $90

Contract facts

Federal

Contract numberSPE2DR26FQQJ9

Also listed asSPE2DR25D9331-SPE2DR26FQQJ9

AgencyDla Troop Support

Awarding officeDla Troop Support

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentDms Pharmaceutical Group Inc

CAGE1UNB0

UEIPX72BSBQTKJ3

NAICS424210

No full NAICS 424210 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDVSPE2DR25D9331

Place of performancePARK RIDGE IL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startFeb 27, 2026

PoP end (current)Mar 20, 2026

Obligated$275K

Current value$275K

Potential value$275K

4571034480!GAMIFANT 100 MG/20 ML VIAL 20ML is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $275K ($275K obligated). Current period of performance ends Mar 20, 2026. Place of performance: PARK RIDGE IL.

4571034480!GAMIFANT 100 MG/20 ML VIAL 20ML

Recompete timing

Public

● Past PoP end (154 days ago)

Current PoP ended Mar 20, 2026 (154 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Dms Pharmaceutical Group Inc — $737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).

% of firm-wide obligated ($737.3M) · all agencies

Department of Defense (DOD)$737.1M · 100%Department of Veterans Affairs (VA)$193K · 0%

Open full company profile →

Related awards

Same parent · incumbent

SPE2D026F0120

8511978882!OTHER MEDICAL

$248K

Apr 26, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract SPE2DR26FQQJ9?

SPE2DR26FQQJ9 (4571034480!gamifant 100 MG 20 ML VIAL 20ml) is a Dla Troop Support award with a potential value of $275K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded SPE2DR26FQQJ9?

Dla Troop Support awarded SPE2DR26FQQJ9 to Dms Pharmaceutical Group Inc (potential $275K).

Who is the incumbent on SPE2DR26FQQJ9?

Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Mar 20, 2026.

When does Dms Pharmaceutical Group Inc’s SPE2DR26FQQJ9 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 20, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 1, 2026 · refreshed monthlyLatest procurement action Feb 27, 2026